Search results for "adjuvants"

showing 10 items of 151 documents

An assessment of prime‐boost vaccination schedules with AS03A‐adjuvanted prepandemic H5N1 vaccines: a randomized study in European adults

2012

Please cite this paper as: Gillard et al. (2012) An assessment of prime‐boost vaccination schedules with AS03A‐adjuvanted prepandemic H5N1 vaccines: a randomized study in European adults. Influenza and Other Respiratory Viruses DOI: 10.1111/j.1750‐2659.2012.00349.x. Background  Long‐term persistence of immune response and safety of an H5N1 prepandemic influenza vaccine adjuvanted with AS03 (an α‐tocopherol oil‐in‐water emulsion‐based adjuvant system) was evaluated using various prime‐boost schedules that mimicked potential pandemic scenarios (NCT00430521). Methods  Five hundred and twelve healthy adults aged 18–60 years received primary vaccination with one or two doses (0, 21 days schedule…

AdultMaleAdolescentalpha-TocopherolImmunization SecondaryAntibodies ViralAS03Young Adultprime‐boostAdjuvants ImmunologicInfluenza HumanHumansAdjuvantImmunization ScheduleInfluenza A Virus H5N1 SubtypeVaccinationOriginal ArticlesH5N1Hemagglutination Inhibition TestsMiddle AgedAntibodies NeutralizingTreatment OutcomeInfluenza VaccinesOriginal ArticleFemaleinfluenzaprepandemicInfluenza and Other Respiratory Viruses
researchProduct

Lenograstim in preventing chemotherapy-induced febrile neutropenia in patients with soft tissue sarcoma

2013

Background: Neutropenia and its complications represent one of the principal dose-limiting toxicity issues in chemotherapeutic regimens for soft tissue sarcoma. Prophylactic granulocyte colony-stimulating factor (G-CSF) reduces the risk of febrile neutropenia (FN). The correct timing of G-CSF administration should be considered in order to optimize the prophylactic treatment. Patients and Methods: Patients (≥18 years old) affected by soft tissue sarcoma and treated with epirubicin and ifosfamide, underwent prophylactic treatment with G-CSF (lenograstim at 263 μg) from day 5 to day 9. The proportion of patients experiencing FN and G4 neutropenia was considered. Results: A total of 36 patient…

AdultMaleNeutropeniaSettore MED/06 - Oncologia MedicaAntineoplastic AgentsSarcomaSoft Tissue Neoplasmslenograstrim sarcoma neutropeniaMiddle AgedLenograstim Febrile Neutropenia Soft tissue sarcomaLenograstimRecombinant ProteinsYoung AdultAdjuvants ImmunologicGranulocyte Colony-Stimulating FactorHumansFemaleIfosfamideAgedEpirubicin
researchProduct

Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccinatio…

2009

Priming a population with a pre-pandemic vaccine is being considered to maximize the response upon subsequent vaccination with a true pandemic vaccine more closely matched to the causative pandemic strain. The present study explored this prime-boost concept by evaluating different primary schedules with the pre-pandemic A/Vietnam/1194/2004(NIBRG-14) vaccine, containing 3.75 microg of HA, followed by a 6-month booster with a vaccine formulated with 3.75 microg HA of either the same strain or with A/Indonesia/05/2005(IBCDC-RG2), a heterologous strain from a different clade. In this multicentre, open, randomized study (NCT00430521) we measured immune responses in four groups (N = 48-60) of adu…

AdultMalePediatricsmedicine.medical_specialtyAdolescentCross Protectionmedicine.medical_treatmentPopulationImmunization SecondaryBooster doseAntibodies ViralYoung AdultAdjuvants ImmunologicImmunityInfluenza Humanparasitic diseasesmedicineHumansAS03educationeducation.field_of_studyBooster (rocketry)Influenza A Virus H5N1 SubtypeGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryPublic Health Environmental and Occupational HealthHemagglutination Inhibition TestsMiddle AgedImmunity HumoralVaccinationInfectious DiseasesImmunizationInfluenza VaccinesImmunologyMolecular MedicineFemalebusinessAdjuvantVaccine
researchProduct

Quality of life, depression and fatigue in mildly disabled patients with relapsing–remitting multiple sclerosis receiving subcutaneous interferon bet…

2011

Background: The precise relationships among quality of life, depression, fatigue and cognitive impairment in multiple sclerosis (MS) are complex and poorly understood. Objective: To assess the effects of subcutaneous interferon beta-1a on quality of life, depression and fatigue over 3 years in the COGIMUS study, and to examine the relationship between these outcomes and baseline cognitive status. Methods: COGIMUS was an observational 3-year trial assessing cognitive function in 459 patients with relapsing–remitting MS treated with subcutaneous interferon beta-1a. Results: In total, 331 patients completed the study (168 received interferon beta-1a, 44 µg subcutaneously three times weekly, a…

AdultMaleQuality of lifeLongitudinal studymedicine.medical_specialtyInjections Subcutaneousmultiple sclerosisRelapsing-Remitting Multiple SclerosisInterferon beta 1aYoung AdultMultiple Sclerosis Relapsing-RemittingAdjuvants ImmunologicQuality of lifeInternal medicinemedicineHumansYoung adultFatigueDepression (differential diagnoses)AgedDepressionbusiness.industryCognitive function; Depression; Fatigue; Interferon beta 1a; Longitudinal study; Quality of life; Relapsing-Remitting Multiple SclerosisMultiple sclerosisCognitive disorderInterferon beta-1aInterferon-betaMiddle Agedmedicine.diseaseClinical trialNeurologyPhysical therapymultiple sclerosis cognition interferon betaFemaleSettore MED/26 - NeurologiaCognitive functionNeurology (clinical)Longitudinal studyCognition DisordersbusinessInterferon beta-1amedicine.drugMultiple Sclerosis Journal
researchProduct

The Italian Multiple Sclerosis Database Network (MSDN): The risk of worsening according to IFNβ exposure in multiple sclerosis

2006

We evaluated the risk of worsening according to the length of exposure to interferon beta (IFNβ)ina large cohort of 2090 multiple sclerosis patients collected by the Italian MS Database Network. Overall 44-140 patient-visits with a follow-up of 22-143 patient-years were evaluated. Forty-one per cent of patients were exposed to IFNβ for up to 2 years, 39% for 2- 4 years and 20% for more than 4 years. A Cox regression model was used to analyse two clinical outcomes: disability progression and worsening of relapse rate. The technique of propensity score was applied to reduce bias in the comparison of non-randomized groups. The risks of disability progression (HR=0.23; 95% CI: 0.17 - 0.30) and …

AdultMaleTime Factorscomputer.software_genreCentral nervous system diseaseCohort Studies03 medical and health sciencesDisability Evaluation0302 clinical medicineAdjuvants ImmunologicmedicineHumansImmunologic Factors030212 general & internal medicineRisk factorMULTIPLE SCLEROSISDemographyProportional Hazards ModelsRISKAnalysis of VarianceDatabasebusiness.industryProportional hazards modelMultiple sclerosisInterferon-betaIFNP; Long term effectiveness; Multiple sclerosis; Observational studies;Middle Agedmedicine.diseaseTreatment OutcomeNeurologyDatabases as TopicItalyPropensity score matchingDisease ProgressionRegression AnalysisObservational studyFemaleNeurology (clinical)Analysis of variancebusinesscomputer030217 neurology & neurosurgeryCohort study
researchProduct

Influence of Thymopentin on Antibody Response, and Monocyte and T Cell Function in Hemodialysis Patients Who Fail to Respond to Hepatitis B Vaccinati…

1990

We investigated the influence of thymopentin as an adjuvant for hepatitis B vaccination on in vitro monocyte and T cell function and in vivo antibody response in a prospective, placebo-controlled double-blind trial in 20 low- and nonresponders to hepatitis B vaccination on chronic hemodialysis. 50 mg thymopentin was given subcutaneously twice per week for 3 weeks, followed by 1 intramuscular injection of 40 micrograms HB-Vax and 3 subsequent injections of thymopentin. After 1 month, the patients were boostered with 40 micrograms HB-Vax. There was no significant difference in T cell and monocyte function after administration of thymopentin, as determined in vitro. After 3 months, 3 patients …

AdultMaleViral Hepatitis VaccinesT-Lymphocytesmedicine.medical_treatmentT cellThymopoietinsMonocytesAdjuvants ImmunologicRenal DialysismedicineHumansThymopentinProspective StudiesHepatitis B AntibodiesAgedRandomized Controlled Trials as TopicAged 80 and overbusiness.industryMonocyteAntibody titerMiddle AgedHepatitis BHepatitis Bmedicine.diseasePeptide FragmentsThymus HormonesVaccinationmedicine.anatomical_structureImmunologyFemaleThymopentinIntramuscular injectionbusinessAdjuvantmedicine.drugNephron
researchProduct

Usefulness of abdominal ultrasonography in the analysis of endoscopic activity in patients with Crohn's disease: changes following treatment with imm…

2013

The objective of this study was to analyze the accuracy of abdominal ultrasonography (AUS) in the assessment of mucosal healing in patients with Crohn's disease (CD) receiving immunomodulators and/or biological treatment, with ileocolonoscopy as the reference standard.Thirty patients were included in a prospective longitudinal study. All patients underwent ileocolonoscopy and AUS before and after a minimum of one year of treatment. The Crohn's Disease Endoscopic Inflammatory Index of Severity (CDEIS) was used for endoscopic assessment whereas AUS was analyzed by means of bowel wall thickness, color Doppler grade and percentage of increase of parietal enhancement after contrast injection.In …

AdultMalemedicine.medical_specialtyAdolescentDoppler echocardiographySeverity of Illness IndexEndoscopy GastrointestinalYoung AdultIntestinal mucosaAdjuvants ImmunologicCrohn DiseaseMedicineHumansImmunologic FactorsProspective StudiesBiological response modifiersIntestinal MucosaUltrasonography Doppler ColorCrohn's diseasemedicine.diagnostic_testbusiness.industryTumor Necrosis Factor-alphaGastroenterologyMucous membraneMagnetic resonance imagingGeneral Medicinemedicine.diseaseEndoscopymedicine.anatomical_structureAbdominal ultrasonographyFemaleRadiologybusinessFollow-Up StudiesJournal of Crohn'scolitis
researchProduct

Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation A Randomized Clinical Trial

2019

###EgeUn###

AdultMalemedicine.medical_specialtyHerpes Zoster Vaccinemedicine.medical_treatmentvirusesVaccines Synthetic/administration & dosageHematopoietic stem cell transplantationPlaceboInjections IntramuscularTransplantation Autologous01 natural sciencesHerpes Zoster Vaccine/administration & dosage03 medical and health sciences0302 clinical medicineAutologous stem-cell transplantationAdjuvants ImmunologicInternal medicinehemic and lymphatic diseasesmedicineHumansSingle-Blind Method030212 general & internal medicine0101 mathematicsAdverse effectHospitalization/statistics & numerical dataProportional Hazards ModelsImmunocompromised hostintegumentary systembusiness.industryIncidence (epidemiology)010102 general mathematicsvirus diseasesGeneral MedicineMiddle AgedNeuralgia Postherpetic/prevention & controlTransplantationsurgical procedures operativeHerpes Zoster/epidemiologyhematopoietic stem cell transplantationoncologyincidenceFemaleZoster vaccinebusinessFollow-Up Studiesmedicine.drug
researchProduct

Incidence of Narcolepsy in Germany

2015

Study objectives Following the 2009 pandemic, reports of an association between an AS03 adjuvanted H1N1 pandemic influenza vaccine and narcolepsy were published. Besides determining background incidence rates for narcolepsy in Germany this study aimed at investigating whether there was a change in incidence rates of narcolepsy between the pre-pandemic, pandemic, and the post-pandemic period on the population level. Design Retrospective epidemiological study on the incidence of narcolepsy with additional capture-recapture analysis. Setting German sleep centers. Patients or participants Eligible were patients with an initial diagnosis of narcolepsy (ICD10 Code G47.4) within the period from Ja…

AdultMalemedicine.medical_specialtyPediatricsAdolescentInfluenza vaccineRate ratioIncidence of Narcolepsy in GermanyYoung AdultInfluenza A Virus H1N1 SubtypeAdjuvants ImmunologicPhysiology (medical)GermanyEpidemiologyInfluenza HumanmedicineHumansYoung adultChildNarcolepsyRetrospective Studiesbusiness.industryIncidence (epidemiology)IncidenceVaccinationInfant NewbornInfantRetrospective cohort studyGeneral Medicinemedicine.diseaseInfluenza VaccinesChild PreschoolObservational studyFemaleNeurology (clinical)SeasonsbusinessSleepNarcolepsy
researchProduct

Intratympanic Dexamethasone and Hyaluronic Acid in Patients with Low-Frequency and Ménière's-Associated Sudden Sensorineural Hearing Loss

2005

Steroids are widely used for the treatment of cochleovestibular disorders. Direct steroid application in the middle ear cavity, when combined with a round window membrane permeability-modulating substance, increases the level of the steroid reaching the target cells. We measured hearing in patients with idiopathic isolated low-frequency sensorineural hearing loss and in patients with sudden sensorineural hearing loss and a history of Ménière's disease. Contradictory reports about effectiveness of intratympanic steroid therapy on vertigo control and hearing improvement in patients with Ménière's disease exist in the literature.Eighteen patients with isolated low-frequency idiopathic sudden s…

AdultMalemedicine.medical_specialtyTympanic MembraneHearing lossHearing Loss SensorineuralAnti-Inflammatory AgentsInjections IntralesionalAudiologyDexamethasoneAdjuvants ImmunologicVertigootorhinolaryngologic diseasesmedicineHumansProspective StudiesHyaluronic AcidProspective cohort studyMeniere DiseaseDexamethasoneRound windowbiologymedicine.diagnostic_testbusiness.industryAuditory ThresholdHearing Loss SuddenMiddle Agedbiology.organism_classificationmedicine.diseaseSensory SystemsTreatment Outcomemedicine.anatomical_structureOtorhinolaryngologyMiddle earAudiometry Pure-ToneFemaleSensorineural hearing lossNeurology (clinical)medicine.symptomAudiometrybusinessmedicine.drugOtology & Neurotology
researchProduct